Open Access

Update on the distribution of Mansonella perstans in the southern part of Cameroon: influence of ecological factors and mass drug administration with ivermectin

  • Samuel Wanji1, 2Email author,
  • Dizzle Bita Tayong1, 2,
  • Laura E. Layland4, 5,
  • Fabrice R. Datchoua Poutcheu1, 2,
  • Winston Patrick Chounna Ndongmo1, 2,
  • Jonas Arnaud Kengne-Ouafo1, 2,
  • Manuel Ritter4, 5,
  • Nathalie Amvongo-Adjia2,
  • Fanny Fri Fombad1, 2,
  • Charity Nya Njeshi2,
  • Armand Seraphin Nkwescheu3,
  • Peter A. Enyong1, 2 and
  • Achim Hoerauf4, 5
Parasites & Vectors20169:311

https://doi.org/10.1186/s13071-016-1595-1

Received: 12 March 2016

Accepted: 17 May 2016

Published: 31 May 2016

Abstract

Background

Mansonellosis remains one of the most neglected of tropical diseases and its current distribution in the entire forest block of southern Cameroon is unknown. In order to address this issue, we have surveyed the distribution of Mansonella perstans in different bioecological zones and in addition, elucidated the influence of multiple rounds of ivermectin (IVM) based mass drug administration (MDA).

Methods

A mixed design was used. Between 2000 and 2014, both cross-sectional and longitudinal surveys were carried out in 137 communities selected from 12 health districts belonging to five main bioecological zones of the southern part of Cameroon. The zones comprised of grassland savanna (GS), mosaic forest savanna (MFS), forested savanna (FS), deciduous equatorial rainforest (DERF) and the dense humid equatorial rainforest (DHERF). The survey was carried out in some areas with no treatment history as well as those currently under IVM MDA. Individuals within the participatory communities were screened for the presence of M. perstans microfilariae (mf) in peripheral blood by the calibrated thick film method to determine both prevalence and geometric mean intensities at the community level.

Results

Apart from sporadic cases in savanna areas, distribution of M. perstans was strongly linked to the equatorial rainforest zones. Before CDTI, the highest mean prevalence (70.0 %) and intensity (17,382.2 mf/ml) were obtained in communities in Mamfes’ DHERF areas followed by communities in the DHERF zone of Lolodorf (53.8 % and 7,814.8 mf/ml, respectively). A longitudinal survey in Mamfe further showed that M. perstans infections had reduced by 34.5 % in DERF (P < 0.001) but not DHERF zones after ten years of IVM MDA. Further data from the cross-sectional study revealed that there was a decrease in prevalence in DHERF zones only after ten years of MDA. In DERF zones however, the infection was relatively lower after four years of MDA.

Conclusions

The distribution of M. perstans in the southern part of Cameroon varies with bioecological zones and IVM MDA history. The zones with high prevalence and intensities lie in forested areas while those with low endemicity are in the savanna areas. MDA with ivermectin induced significant reduction in the endemicity of mansonellosis in the decidious equatorial rainforest. In contrast, the prevalence and intensity remained relatively high and stable in the dense humid equatorial rainforest zones even after a decade of mass drug administration with ivermectin. Since it is known that M. perstans down-regulates host's immune system, the findings from this work would be useful in designing studies to understand the impact of M. perstans on host immune response to vaccination and co-infection with other pathogens such as Mycobacterium spp. and Plasmodium spp. in areas of contrasting endemicities.

Keywords

Mansonellosis Mansonella perstans Microfilariae Distribution Prevalence Intensity Bioecological zones Ivermectin MDA Cameroon

Background

Mansonella perstans (formerly Dipetalonema perstans) is a vector-borne human filarial nematode, transmitted by tiny blood-sucking midges of the genus Culicoides and is the causative agent of mansonellosis [1]. It is one of the most prevalent human parasites in sub-Saharan Africa (reported in 33 countries) and over 114 million people are infected throughout the continent [1]. On the west coast of Africa, it spreads from Senegal to Angola, through central Africa, north to southwest Sudan, east to Uganda, Kenya and Tanzania and south to Zimbabwe [2]. In most affected countries (Cameroon, Nigeria, Ghana, Sierra Leone, Ivory Coast, Zambia and Uganda), the disease occurs mainly among poor people living in rural villages [2, 3]. Although absent in most northern and southern regions of Africa and Asia, M. perstans infections are prevalent in Central and South America as well as the Caribbean [1].

Infections with M. perstans present mild pathology compared to infections with other filarial parasites such as Wuchereria bancrofti, Brugia malayi, Onchocerca volvulus and Loa loa. However, the pathogenicity of M. perstans infection has recently been reconsidered since Bregani et al. [4], documented that M. perstans has the ability to induce a variety of clinical features, including angioedema Calabar-like swellings, pruritus, fever, headache, high eosinophilia, abdominal pain, arthralgia, and neurologic manifestations. In addition, people harbouring the parasite have reported bouts of itchiness and dizziness [5] and there are reports that M. perstans is possibly involved in the development of ocular filariasis as well [6]. Infections with M. perstans have also been shown to induce an immunosuppressive environment in the host [1] through the involvement of a pleiotropic immunomodulatory cytokine IL-10 [7, 8]. IL-10 is well known for its ability to down regulate T helper 1-type responses such as IFN-gamma secretion and activation of monocytes/macrophages [9] and as such, the host may become vulnerable to other pathogens gaining access and invading a dampened immune system.

No specific treatment exists for mansonellosis and ivermectin (IVM), widely used for mass drug administration (MDA) for other filariae, has been reported to have little effect on the infection through community directed treatment with ivermectin (CDTI) [10]. Mebendazole has also been shown to have moderate effect on M. perstans [11]. Although rainforest areas and warm climates seem to favour M. perstans, a detailed knowledge about the environmental factors that support the vector and may account for the differential distribution of the disease is limited [12, 13], especially in Cameroon. In 1995, Mommers et al. [13] provided an account of the distribution of M. perstans in the southern part of Cameroon; however, prevalence in entire forest block remains unclear since repeated surveys were only performed in a single community. Due to the relevance of this parasite in down-regulating host immunity, we have surveyed the distribution and prevalence of M. perstans infection in major bio ecological zones (grassland savannah, mosaic forest savannah, forested savannah, deciduous equatorial rainforest and dense humid equatorial rainforest) in southern Cameroon. Moreover, we compared prevalence of infection in areas before and > 10 years after IVM MDA introduction. These datasets provide useful tools for designing studies aimed at understanding the impact of M. perstans on host immunity against other pathogens such as Mycobacterium species.

Methods

Study design

This study used a mixed study design (cross-sectional and longitudinal surveys) and was carried out in 137 communities of five main bioecological zones: grassland savannah (GS), mosaic forest savannah (MFS), forested savannah (FS), deciduous equatorial rainforest (DERF) and dense humid equatorial rainforest (DHERF), belonging to 12 health districts of Cameroon from the year 2000 to 2014 (Fig. 1). Based on the stratification of health districts, communities were randomly selected as well as households within the communities. To establish the possible impact of IVM MDA on M. perstans distribution, the health districts in different bioecological zones were classified into three main groups. The first group was health districts surveyed before the introduction of IVM MDA or with no treatment history at the time of sampling. The second group was health districts surveyed whilst IVM-MDA has been ongoing and the third group was specific communities of health districts (Mamfe and Nwa) surveyed before and whilst under IVM-MDA. Figure 2 shows in detail, the current years of IVM-MDA in each surveyed health district. In each participatory community, eligible individuals (both males and females) were those that had lived in the communities for at least five years and were at least five years old. Recruited volunteers that met the eligibility criteria gave their full written consent and for children, consent was provided by the child's parent or legal guardian. Details on gender and median age of individuals in the various health districts and bioecological zones are shown in Additional file 1: Figure S1. Each volunteer was screened for the presence of M. perstans microfilariae in peripheral blood. Both prevalence and geometric mean intensities were generated with respect to communities in health districts and statistically compared for the different bioecological zones.
Fig. 1

Bioecological zones in M. perstans endemic areas in cameroon. Map shows sampling areas in relationship to bioecological zones. FS, forest savannah; MFS, mosaic forest savannah; GS, grassland savannah; DERF, deciduous equatorial rainforest; and DHERF, dense habitat equatorial rainforest

Fig. 2

Rounds of mass drug administration programmes in years in M. perstans endemic areas in Cameroon. MDA rounds at the time of sampling in 2013: white = no treatment; pale blue = 4 years; mid-blue = 8 years MDA and dark blue = >10 years. Striped areas refer to sites of longitudinal survey where in, samples were obtained before MDA started and after either 8 (Nwa) or >10 (Mamfe) years

Study site

The study was carried out in communities selected from both rainforest and savanna areas in Cameroon. The climate varied from "Guinea type" in the South and East bioecological zones through equatorial hot and wet in the Littoral, to temperate in the South West and humid savanna/tropical in the North West zones. Warm climates (guinea and temperate type) seem to favour the transmission of M. perstans. The climate of savanna areas are typically humid savanna to tropical forest type and in this study we surveyed three distinct savanna regions. GS: this includes communities of the Nkambe health district of north-west Cameroon. This area is mainly grassland, characterised by sparse trees that are widely spaced to provide an open canopy. Areas of MFS include communities of the Kumbo health district still in the western highlands of Cameroon. The vegetation is mainly grassland crossed with trees growing alongside streams and on hillsides but the tree density is less compared to the forested savanna. FS contained communities of the Nwa health district also in the western highlands of Cameroon. The vegetation here is typically grass with a very high density of trees and has a humid climate. This FS is thus a transition between savanna and forest zones. DERF areas comprised communities in Bare, Tombel, Konye, Kumba and Mamfe health districts in the littoral and south-west regions of Cameroon. This type of forest has a warm climate and is characterised with high rainfalls while the dry season is cooler. Also many trees shed their leaves creating a reduction in the canopy thus permitting sunlight to reach the forest floor and hence growth of vigorous ground vegetation [14]. Finally, the DHERF comprised some communities of Mamfe, Bertoua, Messamena, Batouri and Lolodorf health districts in the south-west, south and east regions of Cameroon. The climatic conditions remain equal here all year round and are marked with high daily and nightly temperatures as well as heavy daily rainfall. The warmth and high humidity also accounts for the high biological diversity observed in these areas. Unlike the DERF, no leaves are shed here in the dry season, and as such, the DHERF have a well-developed canopy "tier" form of vegetation [14] and can be referred to as primary forests. The majority of the inhabitants of these zones are subsistence farmers and the main cash crops include cocoa, rubber, cassava, maize, yams, plantains and bananas. Crops like bananas and plantains as well as their products are cultivated near homes and serve therefore as efficient breeding sites for Culicoides spp. As such, the population is exposed to the bites of the vectors through their activities.

Parasitological screening

Diagnosis of mansonellosis is through the detection and identification of M. perstans mf in peripheral blood [15]. Samples were collected for diagnosis during the day. Thick blood films were prepared from standardized 50 μl finger pricked blood using 75 μl non-heparinised capillary tubes. Smears were prepared by spreading the blood on clean slides covering an area of 1.5 × 2.5 cm and allowed to air-dry. In the laboratory, the blood smears were dehaemoglobinised using tap water for 10 to 15 min and were fixed with methanol for 1 min. Smears were later stained in 10 % Giemsa for 45 min, rinsed in distilled water and allowed to air-dry [3, 16]. Slides were read under a light microscope at a magnification of 10× by trained technicians. Parasites were identified using the mf identification keys of Orihel et al. [17]. In study areas co-endemic for Loa loa, another filarial species with blood dwelling mf, identification was done by two well-trained technicians in a blind manner. Mf counts were expressed as microfilariae per millilitre of blood (mf/ml).

Data analysis

Statistical analyses were performed using the software SPSS (IBM SPSS Statistics 20; Armonk, NY) and GraphPad PRISM version 5.02 for Windows (GraphPad Software, Inc., La Jolla, USA, www.graphpad.com). P-values of less than 0.05 were considered statistically significant. For data that were not normally distributed, the following tests were performed: Kruskal-Wallis test was performed to compare three groups, followed by a Mann-Whitney U-tests for further pairwise comparisons. For comparisons of continuous parameters, the Spearman rank correlation was used. Mann-Whitney and Kruskal-Wallis tests were used to compare mean prevalence and geometric mean intensity of M. perstans in communities and health districts of the different surveyed bioecological zones. Mf prevalence and geometric mean intensities were also compared with respect to MDA history.

Results

Absence of IVM-MDA programmes reveals a dominant M. perstans prevalence in ERF areas

In this study, we analysed blood samples for M. perstans infection from individuals living in savanna (n = 3,073 individuals in 26 communities) and ERF (n = 2,648 individuals in 29 communities) areas that had not yet started ivermectin MDA programmes (Figs. 1 and 2). Figure 3a, b shows that the prevalence of M. perstans and corresponding mf intensity were significantly higher in ERF geographical areas since very few positive persons were detected in savanna districts (n = 3/3,073). We further subdivided the study area into savanna zones: grassland (GS), forest (FS) and mosaic forest (MFS), and equatorial rainforest (ERF) zones: deciduous equatorial rainforest (DERF) and dense humid equatorial rainforest (DHERF). This revealed that all savanna bioecological zones (MFS, FS and GS) were extremely low in infection whereas both DERF and DHERF zones had high prevalence, up to 100 % in some communities (Fig. 3c) and high mf intensity (Fig. 3d). Further analysis on individual health districts revealed that amongst the health districts in the DHERF region, Mamfe had a significantly higher prevalence of M. perstans infection than Lolodorf or Batouri (Fig. 3e). Significant differences in mf intensities were also revealed upon comparison of Mamfe and Batouri DHERF districts (Fig. 3f). No significant differences were found between Mamfe communities residing in DERF and DHERF areas. Thus, in the absence of any MDA programmes M. perstans infection is restricted to ERF geographical zones. Table 1 provides details about the prevalence and mf intensity in each surveyed community.
Fig. 3

M. perstans infections are prevalent in ERF but not savanna areas. To determine the baseline prevalence (a) and intensity (b) of M. perstans infection prior to MDA in South West and eastern districts of Cameroon, individuals were screened in savannah (n = 3,073) and ERF (n = 2,648) zones that were yet to begin MDA programmes. Prevalence (c) and associated mf counts (d) were then assessed in GS, MFS and FS savannah districts and DERF and DHERF forest districts. Data were then further examined on an individual district level: Nkambe, GS (8 communities/n = 1,167); Kumbo, MFS (8 communities/n = 878); Mamfe, DERF (7 communities/n = 818) and DHERF (9 communities/n = 640); Lolodorf, DHERF (4 communities/n = 290), Batouri, DHERF (9 communities/n = 900); Nwa, FS (10 communities/n = 1,028). Statistical significance of the differences between groups indicated by the brackets were obtained after ANOVA/Kruskal-Wallis or Student's t-test or Mann-Whitney analysis depending on the normal distribution of the data

Table 1

M. perstans prevalence and intensity in five bioecological zones surveyed without any treatment history

Ecological zone

Health district/year of survey

Community

Number surveyed

Number positive

Prevalence (%)

Geometric mean (mf/ml)

  

Bansobi

195

0

0

0

  

Dzeng

186

0

0

0

  

Kifem I

151

0

0

0

GS

Nkambe/2000

Lam

140

0

0

0

  

Njanawa

105

0

0

0

  

Rifem

212

0

0

0

  

Tanyar

52

0

0

0

  

Yang

126

0

0

0

  

Total

1,167

0

0

0

  

Bem

119

0

0

0

  

Chunghe

78

0

0

0

  

Kamine

125

0

0

0

  

Kibbo

94

1

1.06

2,072.8

MFS

Kumbo/2000

Lip

133

0

0

0

  

Mbissa

115

0

0

0

  

Mfume

68

0

0

0

  

Nkanchi

146

0

0

0

  

Total

878

1

0.11

2,072.8

  

Jator

111

0

0.0

0

  

Mbiripkwa

70

0

0.0

0

  

Ngomkow

66

0

0.0

0

  

Ngu

112

1

0.9

13.90

  

Nguri

90

0

0.0

0

FS

Nwa/2000

Nking

96

0

0.0

0

  

Ntem

95

0

0.0

0

  

Nwanti

107

0

0.0

0

  

Nwat

52

0

0.0

0

  

Sabongari

229

1

0.4

13.90

  

Total

1,028

2

0.2

13.90

  

Assam

57

52

91.2

10,402.8

  

Bache

128

70

54.7

1,539.0

  

Kesham

174

104

59.8

1,543.6

DERF

Mamfe/2000

Obonyi 1

121

94

77.7

1,2577.0

  

Obonyi-3

159

119

74.8

4,036.1

  

Okpambe

45

35

77.8

8,743.4

  

Takamanda

134

94

70.1

4,427.3

  

Total

818

568

69.4

4,344.7

  

Ajaman

88

76

86.4

91,380.1

  

Akwa

66

57

86.4

40,762.6

  

Araru

30

21

70.0

2,199.2

  

Babi

26

26

100.0

31,180.4

DHERF

Mamfe/2000

Babong

181

95

52.5

2,735.4

  

Ekoneman

24

14

58.3

12,749.6

  

Mbofong

39

36

92.3

94,757.9

  

Nkoghau

107

63

58.9

11,391.1

  

Ogurang

79

60

75.9

8,699.7

  

Total

640

448

70.0

17,382.9

  

Dem2

115

27

23.5

348.2

  

Djal

114

30

26.3

1,380.9

  

Kamba Mieri

126

19

15.1

811.6

  

Konga

149

105

70.5

3,930.3

DHERF

Batouri/2013

Gabaleta

47

6

12.8

899.4

  

Ngoulmekong

96

52

54.2

2,334.0

  

Nguikouassima

63

20

31.7

589.1

  

Baktala

110

53

48.2

1,226.7

  

Bouam

80

38

47.5

4,573.6

  

Total

900

350

38.9

1,947.7

  

Bibondi

100

55

55.0

4,296.8

DHERF

Lolodorf/2010

Bikalla

94

65

69.1

19,797.5

  

Bikoka

30

11

36.7

1,049.4

  

Ngovayang

66

25

37.9

4,905.5

  

Total

290

156

53.8

7,814.8

Abbreviations: GS grassland savanna, MFS mosaic forest savanna, FS forested savanna, DERF deciduous equatorial rainforest, DHERF dense humid equatorial rainforest, mf/ml M. perstans microfilariae per millilitre of blood

Mansonella perstans prevalence and intensity in areas surveyed under MDA programmes reveal varying trends

Tables 2 and 3 show the current prevalence and intensity in ERF and FS districts that have had multiple rounds of IVM-MDA. With health districts surveyed under IVM-MDA for 4 and 8 years (Table 2), the prevalence ranged from 0.5 % in the FS of Nwa (8 years of IVM-MDA) through 23.2 % in the DERF of Bare (4 years of IVM-MDA) to 51.0 % in the DHERF of Messamena (8 years of IVM MDA). The same trend was observed in the mf geometric mean intensity. Therefore, both prevalence and intensity of M. perstans infection were highest in the DHERF compared to DERF and FS in communities surveyed 4 and 8 years under IVM-MDA. Whereas, with health districts surveyed with over a decade of treatment (Table 3), the highest prevalence was observed in the DERF of Mamfe (49.73 %) and the least in the DERF of Kumba (7.9 %). The mf intensity was rather high in the DHERF of Mamfe compared to the other health districts (Additional file 2).
Table 2

Prevalence and mean mf intensity of M. perstans in zones under CDTI for 4–8 years (Bare, Bertoua, Messamena and Nwa)

Ecological zone

Health district/year of survey

CDTI Status

Community

Number examined

Number positive

Prevalence (%)

Geometric mean (mf/ml)

   

Mandjibo

67

11

16.4

209.6

   

Mbarembeng I

95

4

4.2

62.6

   

Mbarembeng II

72

3

4.2

29.2

   

Mbie

27

12

44.4

502.6

  

4 years

Mounko

67

3

4.5

85.6

DERF

Bare/2010

Mpaka

73

1

1.4

13.9

   

Ndom

103

36

35.0

1,410.3

   

Ndouembot

22

17

77.3

15,322.1

   

Ndouenke

29

21

72.4

7,965.2

   

Nkoniambot

174

51

29.3

314.9

   

Nkoniankoniama

19

14

73.7

3,546.0

   

Nkounianke

124

29

23.4

912.5

   

Total

872

202

23.2

1,116.7

   

Bombi

112

82

73.2

4,162.3

   

Deng-Deng

105

40

38.1

3,354.1

DHERF

Bertoua/2013

8 years

Kanda

126

33

26.2

5,341.8

   

Mbethen 2

112

86

76.8

3,193.2

   

Ndemba 1

106

40

37.7

767.8

   

Total

561

281

50.1

3,062.6

   

Aviation

114

22

19.3

222.5

   

Bissoua 2

155

107

69.0

3,758.8

   

Doume Village

42

10

23.8

209.4

   

Koum

45

26

57.8

898.4

   

Labba

34

27

79.4

9,189.4

DHERF

Messamena/2013

8 years

Mayos

74

39

52.7

1,757.1

   

Meba

47

35

74.5

2,532.2

   

Messamena Village

78

46

59.0

5,275.1

   

Nkomzuh

58

31

53.4

1,180.3

   

Ntollock

52

14

26.9

75.9

   

Soleye

163

83

50.9

1,976.9

   

Total

862

440

51.0

2,115.8

   

Jator

115

2

1.7

150.0

   

Mbiripkwa

137

0

0

0

   

Ngomkow

156

1

0.6

316.0

   

Ngu

143

0

0

0

FS

Nwa/2013

8 years

Nguri

143

0

0

0

   

Nking

108

0

0

0

   

Ntem

153

0

0

0

   

Nwanti

140

1

0.7

111.4

   

Nwat

124

1

0.8

13.9

   

Sabongari

110

1

0.9

1,509.8

   

TOTAL

1329

6

0.5

175.8

Abbreviations: GS grassland savanna, MFS mosaic forest savanna, FS forested savanna, DERF deciduous equatorial rainforest, DHERF dense humid equatorial rainforest, mf/ml M. perstans microfilariae per millilitre of blood

Table 3

Prevalence and mean mf intensity of M. perstans in the DERF and DHERF surveyed after over a decade under CDTI (Mamfe, Konye, Kumba and Tombel health districts)

Ecological zone

Health district/year of survey

CDTI status

Community

Number examined

Number positive

Prevalence (%)

Geometric mean (mf/ml)

   

Assam

59

40

67.80

4,763.3

DERF

Mamfe (2010 & 2013)

>10 years

Bache

104

47

45.20

1,146.1

   

Kesham

126

55

43.7

972.5

   

Okpambe

87

45

51.70

3,173.6

   

Total

376

187

49.73

1,934.8

   

Afap

26

5

19.20

21.8

   

Ayukaba

116

12

10.34

1,128.1

   

Babong

93

68

73.11

4,971.1

   

Bokwa

60

20

33.33

274.3

   

Ebam

95

2

2.11

801.3

   

Eshobi

90

36

40.0

1,154.9

DHERF

Mamfe (2010 & 2013)

>10 years

Eyanchang

113

1

0.97

4,161.2

   

Kajifu

100

22

22.0

3,101.8

   

Mbakem

40

4

10.0

508.7

   

Mbatop

115

9

7.83

299.7

   

Mbeme

85

17

20.0

1,149.3

   

Momboh

88

9

10.22

112.2

   

Nkoghau

60

38

63.33

1,795.4

   

Nyang

32

22

68.75

7,976.6

   

Ogurang

86

66

76.74

12,170.2

   

Taboh

77

11

14.30

73.1

   

Total

1276

342

26.80

2,445.1

   

Baduma

84

7

8.3

369.3

   

Bakolle

78

5

6.4

155.7

   

Bolo

107

11

10.3

165.6

   

Dikomi Bafaw

101

12

11.9

72.6

   

Eboko Bajor

89

10

11.2

216.7

DERF

Konye (2010 & 2013)

>10 years

Kokaka

74

14

35.1

122.1

   

Kombone

97

11

11.3

204.3

  

Kurume

45

5

11.1

86.0

   

Matondo

107

5

4.7

206.9

   

Weme

103

17

16.5

385.6

   

Total

885

97

11.0

183.2

   

Bai Bikom

91

0

0

0

   

Bai Manya

89

2

2.2

150.0

   

Bai Panya

43

0

0

0

   

Bakumba

76

11

14.5

971.0

   

Bambele

66

11

16.7

377.0

   

Big Massaka

157

7

4.5

2,234.2

   

Bikoki

46

30

65.2

1,077.6

   

Boa Bakundu

60

6

10

451.7

DERF

Kumba (2010 & 2013)

>10 years

Bobanda

32

4

12.5

1,651.5

   

Ediki

101

8

7.9

85.9

   

Kotto Barombi

66

0

0

0

   

Kumu-Kumu

34

11

32.4

418.8

   

Marumba I

50

0

0

0

   

Marumba II

68

0

0

0

   

Mbalangi

100

2

2.0

359.1

   

New Town

96

3

3.1

316.0

   

Pete Bakundu

34

0

0

0

   

Small Massaka

33

3

9.1

1,586.6

   

Total

1241

98

7.9

667.7

   

Bulutu

86

17

19.8

148.2

   

Ehom

74

6

8.1

70.8

   

Kack

142

28

19.7

337.5

   

Mbabe

68

20

29.4

2,610.1

   

Mbule

73

37

50.7

2,110.6

   

Mile 18

54

6

11.1

279.5

DERF

Tombel (2010 & 2014)

>10 years

Mpako 1

63

21

33.3

1,052.8

  

Ndom

67

18

26.9

609.2

   

Ngab

53

14

26.4

392.9

   

Ngusi

102

11

10.8

2,452.9

   

Nlog

107

38

35.5

4,003.6

   

Nsuke

113

18

15.9

1,646.2

   

Peng

81

22

27.2

616.8

   

Ndabekom

87

25

28.7

1,321.1

   

Total

1,170

281

24.0

1,081.0

Abbreviations: GS grassland savanna, MFS mosaic forest savanna, FS forested savanna, DERF deciduous equatorial rainforest, DHERF dense humid equatorial rainforest, mf/ml M. perstans microfilariae per millilitre of blood

Longitudinal surveys in Mamfe reveals reduced M. perstans infection in DERF but not DHERF zones after > 10 years IVM-MDA

As shown in Fig. 3, in the absence of IVM-MDA M. perstans infections were highly prevalent in ERF zones. The district of Mamfe in the South West of Cameroon is an ERF geographical zone and we performed a longitudinal study of M. perstans infection between 2000 and 2013. Figure 4a, b provides comparative data for the prevalence and mf counts in Mamfe before the start of IVM-MDA (0 MDA; n = 771 individuals) and after more than 10 years of therapy (>10 MDA; n = 615 individuals). Data from these seven communities showed both trends of decrease and increase, therefore we divided the communities into those residing in DERF and DHERF zones (Fig. 1). Interestingly, communities residing in DERF zones (Assam, Bache, Kesham and Okpambe) presented a decreased prevalence (Fig. 3c) and mf intensities (Fig. 4d) whereas those in DHERF zones (Babong, Oguarag and Nkoghau) did not (Fig. 4e, f). Tables 1 and 3 show the data for each community before and after IVM-MDA treatment. Table 4 shows the percentage reduction in both prevalence and mf intensity of M. perstans in the communities of Mamfe in DERF and DHERF zones. In Fig. 3e, f we have also shown that the FS geographical zone Nwa had very low M. perstans infection prior to MDA (0.2 %) and in 2013, after > 8 years of MDA only 6/1,329 individuals were found microfilaraemic (Additional file 2: Figure S2; Additional file 3 Table S1). These data reveal two important situations: (i) FS zones contain little M. perstans and this has not changed before or after MDA treatment; and (ii) IVM treatment appears to have an effect on M. perstans infections in DERF but not DHERF zones (Additional file 2: Figure S2; Additional file 3 Table S1).
Fig. 4

Longitudinal surveys in Mamfe reveal dampened M. perstans infection in DERF but not DHERF zones after >10 years MDA. a Prevalence and b mf intensity in Mamfe district (7 communities) prior to IVM therapy (0 MDA; n = 771) and after at least 10 years of MDA treatment (>10 MDA; n = 615). Analysis of individuals in DERF located communities of Mamfe (Assam, Bache, Kesham and Okpambe) revealed reduced prevalence and mf intensity c and d respectively): 0 MDA; n = 404 and > 10 MDA; n = 376. Infection in individuals of the DHERF communities of Mamfe (Babong, Ogurang and Nkoghau) remained unchanged or trended upwards (e and f): 0 MDA; n = 367 and > 10 MDA; n = 239. Symbols at each time point represent mean prevalence (%) or mf intensity (mf/ml) from one community

Table 4

Percentage reduction in M. perstans prevalence and intensity in selected communities of Mamfe and Nwa surveyed before and under CDTI MDA

Regions

Bioecological zones

Health district

Prevalence (%)

  

Geometric mean

 

Before IVM MDA

Under IVM MDA

% reduction

χ 2

P-value

Before IVM MDA

Under IVM MDA

% reduction

P-value

South west

DERF

Mamfe

64.60

49.73

23.02

0.7529

0.335

2,957.8

1,934.8

34.58

< 0.0001

DHERF

59.40

71.97

-21.16

10.6411

0.001

5,800.9

5,743.6

0.99

< 0.0001

North west

FS

Nwa

0.20

0.50

-150.00

0.0331

0.281

13.90

175.8

-1164.74

< 0.0001

Abbreviations: DERF deciduous equatorial rainforest, DHERF dense humid equatorial rainforest, FS forested savanna, IVM MDA ivermectin mass drug administration (χ 2 test was used to compare prevalence rates before and under treatment; t-test was used to compare mean intensity of infection before and under treatment)

Comparisons of DHERF communities following multiple MDA rounds reveals reduced prevalence in the south-western but not eastern Cameroon

Since M. perstans prevalence and intensities were different in DERF vs DHERF communities in Mamfe (Fig. 4), we further compared M. perstans infections in other DHERF areas that had had zero (Lolodorf and Batouri), 8 (Messemena and Bertoua) or > 10 rounds of MDA (Mamfe). Interestingly, prevalence and intensities were not significantly altered between 0 or 8 rounds of MDA but after more than 10 years, M. perstans infection rates were significantly reduced (Fig. 5a, b). To rule out that the observed reduction in Mamfe after 10 years was not due to simply lower prevalence to begin with, we also compared Mamfe levels prior to MDA and here, prevalence and mf levels were significantly higher than in 2013 (Fig. 5b, c). Moreover, prevalence rates in "Mamfe 0" were also significantly higher than in Lolodorf, Batouri and Messamena as well (Fig. 5b, P < 0.001). With regards to mf levels however, only individuals in Lolodorf showed significantly more mf/ml than those in Mamfe (Fig. 5d, P < 0.001) (Additional file 2).
Fig. 5

Reduced prevalence of M. perstans infection following multiple rounds of IVM-MDA in Mamfe DHERF district but not in DHERF areas in the East. a, b Prevalence of M. perstans infection in community members residing in DHERF zones prior to MDA and after at least 8 or 10 years IVM therapy. In 2013, neither Lolodorf (n = 290) nor Batouri (n = 900) districts in eastern Cameroon had entered in MDA programmes. Messamena (n = 862) and Bertoua (n = 561) districts, also in the East, had received at least 8 rounds of MDA and the South West district of Mamfe had had > 10 rounds MDA (n = 1,276). Mamfe 0 refers to prevalence and intensity prior to MDA therapy (n = 640). c, d show mf counts in the different communities based on rounds of MDA (0, 8 > 10) or per district respectively. Statistical significance of the differences between groups indicated by the brackets were obtained after ANOVA/Kruskal-Wallis or Student's t-test/Mann-Whitney analysis depending on the normal distribution of the data

Communities within DERF zones show lower prevalence and intensity after multiple IVM-MDA rounds

As depicted in Fig. 1, Mamfe can be divided into DERF and DHERF zones. Since M. perstans prevalence and intensity had decreased in the DHERF Mamfe health district after > 10 years of IVM-MDA (Fig. 5a, c), we further compared the effects of > 10 years IVM-MDA on M. perstans in communities in DERF zones. Here, communities in Mamfe (n = 4), Tombel (n = 14), Kumba (n = 18) and Konye (n = 10) were compared. Interestingly, the highest prevalence of M. perstans was found in individuals living in Mamfe (Fig. 6a) and mf intensities were also significantly higher when compared to Konye and Kumba (Fig. 6b, P <0.001). Prevalence rates in communities within Tombel were also significantly higher than those from Konye and Kumba (Fig. 6a, P < 0.001) which was further reflected in mf intensities (Fig. 6b). Table 3 shows a detailed overview of each community. In our final analysis, we compared DERF communities that had had 0, 4 and > 10 years of IVM-MDA. Table 2 provides details about the health district Bare, which at the time of sampling had only participated in IVM-MDA for 4 years. Figure 6c, d shows that in comparison to communities that had received no IVM-MDA (n = 818 individuals, Table 1), both prevalence and intensity levels were lower in communities that had received 4 years of IVM MDA (n = 872 individuals, Table 2) and > 10 years of IVM-MDA (n = 3,672 individuals, Table 3). Thus, in confirmation of the longitudinal study shown in Fig. 4c, there is a general decrease in M. perstans prevalence and intensity in communities within DERF zones that have received 4–10 years of IVM-MDA (Additional file 3 Table S1).
Fig. 6

Kumba district shows the lowest prevalence of M. perstans infection in DERF bioecological zones. a, b show prevalence and mf intensity in M. perstans infected individuals living in DERF bioecological zones after at least 10 years of MDA therapy. Mamfe (n = 376); Tombel (n = 1,170); Konye (n = 885); and Kumba (n = 1,241). c, d show the prevalence and mf numbers in individuals living in DERF zones that had had 0 MDA (Mamfe; n = 404), > 4 years of MDA (Bare; n = 872) and > 10 years of MDA (Tombel, Konye, Kumba and Mamfe; n = 3,672). Statistical significance of the differences between groups indicated by the brackets were obtained after ANOVA/Kruskal-Wallis or Student's t-test/Mann-Whitney analysis depending on the normal distribution of the data

Discussion

The overall objective of this study was to provide a comprehensive overview about the current distribution of M. perstans in Cameroon, taking into consideration the advent of ivermectin MDA. Therefore, using a sample of 14,293 individuals from 137 communities, we determined the prevalence and intensity of M. perstans in five major bioecological zones of Cameroon. We observed that in the absence of MDA programmes, the highest prevalence of mansonellosis was restricted to equatorial rainforest areas since all three different savanna areas had only sporadic infection cases. Indeed, from 3,073 samples from savanna areas, only three individuals in Nkambe (GS), Kumbo (MFS) and Nwa (FS) were microfilaraemic. In contrast, M perstans was extremely prevalent in communities within DHERF and DERF zones with 20/29 communities showing prevalence over 50 %, 12/29 communities over 70 % and 3/29 communities over 90 %. Not a single community was found negative in the forest area. The lowest prevalence (12.8 %) was observed at Gabaleta in Batouri. The geometric mean of mf was also high reaching an average of 91,380.1 and 94,757.9 mf/ml in individuals in Ajaman and Mbofong, respectively, in Mamfe (DHERF). These data show that although M. perstans in Cameroon is widespread this species is largely restricted to ERF zones in which there can be hotspots of intensity. These results correlate with the observations of Akue et al. [18] in Gabon who also found that M. perstans was significantly higher in forest ecosystems than in savannas and lake land areas. Other studies have reported varying levels of M. perstans infection. For example, Noireau et al. reported a prevalence of 22 % in the forest regions of the Chaillu mountains in the Congo [19] and a prevalence of 26.6 % was observed in a community in the dense forest of southern Cameroon [13] but only 12.4 % of inhabitants in the forested Akonolinga health district of Central Cameroon were found to be M. perstans-positive [20]. Our findings of higher prevalence are more in-line with the studies from Asio et al. [21] who reported prevalence of up to 80 % in endemic communities of Uganda.

Cross-sectional surveys in communities of the study districts under treatment showed that although they had received varying rounds of IVM, a higher prevalence was still observed in DERF and DHERF compared to FS. The higher prevalence of M. perstans infection in forest areas (Mamfe, Messamena, Bertoua, Batouri, Lolodorf and some areas of Bare health districts) reflects the environmental conditions desired by the Culicoides spp. vectors. In contrast to GS and MFS areas, the DHERF and DERF zones provide ideal breeding conditions for the vectors. These include a warmer climate, sufficient rainfall and appropriate habitats such as fallen leaves, decaying plantains and banana stems. Moreover, these breeding sites are close to the hosts' dwellings providing an opportunity for parasite transmission. However, it can also not be ruled out that the species of Culicoides responsible for transmitting M. perstans is simply just refined to DHERF and DERF zones. Parallel entomology surveys were not performed with these surveys but future studies should concentrate on identifying the Culicoides spp. in those areas.

The intensity of infection as expressed by the geometric mean of microfilarial load varied across communities of the surveyed health districts. In the no treatment area, the mean ranged from 0 mf/ml in the GS of Nkambe health district through 13.9 mf/ml in the FS of Nwa to 17,382.2 mf/ml in the DHERF of Mamfe and closely followed by the DHERF of Lolodorf with 7,814.8 mf/ml. The same trend was observed with the prevalence in these areas. Moving across the five bioecological zones, the intensity increased from GS, through MFS (mosaic forest savanna) and FS to DERF and DHERF. Nevertheless, the high intensities in the DHERF before IVM MDA still emphasize the conserved nature of this ecological zone, making transmission very possible between the human host and the competent vector. A limitation of this study included the use of thick blood smears for M. perstans diagnosis which may have missed low mf counts. This diagnostic tool was employed so that all samplings from different time periods could be compared with another.

In the health districts under IVM MDA, the highest mean intensity (3,062.6 mf/ml) was observed in the DHERF of Bertoua with 8 years of ivermectin MDA and the lowest (175.8 mf/ml) in the FS of Nwa with equally 8 years of IVM MDA. The health districts under control for over 10 years had relatively lower intensities compared to those of 4 and 8 years. The decreasing trend in intensity observed over time in these bioecological zones with an increase in the number of rounds of IVM consumed is indicative that this drug has partial effect on M. perstans in the human host, although some authors have shown that the drug has no effect on the parasite [14, 20]. The varying intensity and prevalence in our study participants show that bio-ecology plays a defining role in the distribution of M. perstans even without the influence of ivermectin. To elucidate the effect of IVM-MDA on M. perstans, we performed a longitudinal survey using data from 7 communities in Mamfe (screened at 0 MDA and > 10 years IVM-MDA) as a case study. Our initial conclusion was that long-term IVM-MDA in the communities was having little effect on M. perstans infection since study sites showed both trends of increase and decrease. However, further analysis revealed that although the overall prevalence was not significantly reduced in the DERF communities (P = 0.335), the decrease in intensity over 10 years of MDA was significant (P < 0.001 and a 34.58 % reduction). This trend was not reflected in the DHERF communities of Mamfe since the prevalence either remained stagnant or had increased over time. Interestingly, mf levels in Nkoghau were drastically reduced after > 10 years MDA (11,391.1 vs 1,795.4 mf/ml) even though the prevalence were comparable (58.9 vs 63.3 %). Overall, our data indicate that in DERF communities of Mamfe, transmission is reduced due to either a loss of primary forest and thus breeding sites for the vector, due to impact of IVM, which needs at least 10 years to take effect, or possibly a lowered infection rate in the host. Since the reduction in M. perstans was not observed after long-term MDA in DHERF communities of Mamfe, the effects are more likely to be a consequence of habitat destruction. Studies relating M. perstans infection and IVM-MDA have shown contrasting outcomes. For example, Kyelem et al. [22] demonstrated that after multiple rounds of IVM-MDA in south-western Burkina Faso (Dano area), a significant reduction in M. perstans and Wuchereria bancrofti mf was seen in ivermectin-treated communities. However, a follow-up study by the same authors reported that long term administration (14 years) of IVM-MDA in Burkina Faso (Dienkoa) had no effects on M. perstans [23]. Of interest, this latter study was performed in a savanna ("Guinea" type) bioecological zone and there, prevalence of M. perstans infection (0–10.9 %) was higher than those reported in the present study (0–1.06 %) [23]. Research by other teams in Togo and Uganda [24, 25] have also not confirmed the trend of reduced infection rates in M. perstans following IVM seen by Kyelem et al. [22]. These studies were conducted in the early 90's and therefore only a few rounds of IVM treatment would have occurred since CDTI only commenced in 1995. Fischer et al. [24] reported that after IVM intake, prevalence rates were comparable but no data on mf intensity were provided. The study in Uganda [24] followed mf counts during a six month period after IVM administration and noted that prevalence rates remained the same but mf counts dropped by approximately 40 % within the first two weeks of treatment. Interestingly however, mf counts then stabilised and, since it remains unclear whether M. perstans has a microfilarial reservoir in the host, it cannot be stated whether mf are destroyed or eliminated [25]; this is an element that has to be factored into our findings as well. Furthermore, some of these studies were monitored in individuals co-infected with other filariae or in endemic areas for other filariae [2225] and since IVM kills mf of both Onchocerca volvulus and W. bancrofti, immune responses to those dying mf may have some overlapping effects on M. perstans mf. In addition, studies have shown that M. perstans infections down-regulate the host's immune system through the involvement of IL-10 which may facilitate infections to other incoming pathogens [7, 8, 12]. Studies have investigated the impact of filarial infections on coincident intracellular pathogens and demonstrated the interplay between filarial parasite and microbial pathogen, but the influence of the interplay on disease outcome remains unclear [26]. Unlike other filarial infections, infection with M. perstans begins at childhood and the intensity increases with age [5, 27]. We therefore hypothesise that in areas of high M. pertans transmission, the immune response in children infected could be downregulated with negative consequences on the mounting of strong immune responses during childhood vaccinations and to control coincident pathogens. The present study has delineated the endemicity of M. perstans in the forest block of Cameroon and demonstrated that the ecology that favours the vector is of paramount importance. This gives an opportunity to design studies that can compare the immune responses of children to vaccination and other pathogens in contrasting areas of endemicity of M. perstans.

In the east and south, a concrete comparison and conclusion cannot be made for Batouri, Bertoua Messamena and Lolodorf health districts because no baseline data exist for the communities of the bioecological zones. Nevertheless, since the zones belong to the same ecological zone (DHERF), we see that at Batouri and Lolodorf that were not yet under CDTI (no treatment) the prevalence was 38.9 and 53.8 %, respectively, whereas those of Bertoua and Messamena (with 8 years of annual IVM) were 50.1 and 51 %, respectively. These high rates of infection in both non-treated and treated communities of the same bioecological zone may be due to (i) low adherence to treatment due to the presence of L. loa in these areas and consequent fear of severe adverse events; and (ii) little or no effect of IVM on the parasite although this will mean that the same communities be screened at 10 and 12 years after CDTI. Just as the prevalence increased in these zones, the intensity of infection also increased. This is normal if the drug is not effective, these parameters should increase with time. In the FS of Nwa health district, although the prevalence was low, a significant decrease was observed in the mf intensity after 8 years of IVM MDA. The consistent low prevalence in this zone could be due to the ecology of the area (lack of breeding sites as well as the vector) and the lack of heavy infection to propagate transmission, and not the fact that individuals here have received up to 8 rounds of mass treatment with ivermectin.

Comparison of DHERF zones in the east and south-west following multiple MDA rounds revealed a decrease in the prevalence in south-western but not in eastern Cameroon. The observed reduction in Mamfe may be due to: (i) better compliance in Mamfe than in Messamena and Bertoua; (ii) that at least 10 years of IVM treatment are required before MDA begins to have an effect on M. perstans infections; or (iii) changes or destruction of the forest zone in Mamfe over the last decade leading to reduced vector breeding sites and consequent abundance. The persistence of the infection in Messamena and Bertoua despite 8 years of IVM MDA could be due to poor adherence of the population to the MDA programmes as demonstrated by Wanji et al. [28].

Conclusions

This study has demonstrated that M. perstans is highly endemic in the equatorial rainforest areas and low in savanna areas of Cameroon and this has not been affected by long-term IVM-MDA programmes. Before CDTI introduction, the high prevalence and intensities of M. perstans infection were observed in both DERF and DHERF of Mamfe. After a decade of IVM-MDA infection levels had dropped in individuals residing in DERF and not in DHERF communities. The decrease in infection intensity could be either due to IVM-MDA intervention or due to ecological changes over time that have led to a loss of breeding sites and a consequent decrease in the vectors’ abundance. Since it is known that M. perstans downregulates host's immune system, the findings from this work would be useful in designing studies to understand the impact of M. perstans on host immune response to vaccination and co-infection with other pathogens such as Mycobacterium spp. and Plasmodium spp. in areas of contrasting endemicities.

Abbreviations

CDTI, Community directed treatment with ivermectin; DERF, deciduous equatorial rainforest; DHERF, dense humid equatorial rainforest; ERF, equatorial rainforest; FS, forested savannah; GS, grassland savanna; IVM, ivermectin; IVM-MDA, ivermectin mass drug administration; MDA, mass drug administration; Mf, microfilariae; MFS, mosaic forest savanna.

Declarations

Acknowledgements

We thank sincerely the chiefs and entire populations in all the 12 health districts surveyed for accepting and participating in this study, the Cameroon Health System, for all the facilities put in place during the surveys; and to the following persons: Nji Theobald, I. Jato, C. Nsenga Vackam, Longang Yolande, Saïdou Abdoul, Sali A. Saidou, for their assistance during the surveys. The authors are grateful to the study participants for their voluntary participation in the study.

Funding

This work was funded through a grant awarded to SW, LEL and AH from the German Research Council (DFG) within the "African-German Cooperation Projects in Infectiology" (HO 2009/10-1). The work also received financial support from the European Commission, through the Collaborative research project: Enhanced Protective Immunity against Filariasis (EPIAF), grant agreement № 242131.

Availability of data and material

The datasets supporting the conclusions of this article are included within the article and its Additional file 1: Figure S1, Additional file 2: Figure S2, Additional file 3: Table S1.

Authors’ contributions

SW, PAE and AH conceived and designed the study. DBT, WPCN, JAKO, NAA, FFF and CNN acquired data and managed field studies, SW, DBT, LEL and FRDP analysed and interpreted datasets. DBT, LEL and MR wrote the manuscript which was then critically assessed and amended by SW, ASN, PAE and AH. All authors read and approved the final copy of the manuscript.

Authors’ information

AH and LEL are members of the Excellence Cluster Immunosensation (DFG, EXC 1023) and of the German Centre of Infectious Disease (DZIF).

Competing interests

All authors declare that they have no competing interests.

Consent for publication

Not Applicable.

Ethics approval and consent to participate

The study protocol was approved by the "National Ethics Committee of Research for Human Health", Yaoundé, Cameroon. Administrative clearance was obtained from the delegation of public health in the different regions. Participation was strictly voluntary and the objectives, risks and benefits of the study were fully explained to all the participants as described in [29] on perceptions of consent, permission structures and approaches to the community in north-west Cameroon.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Parasite and Vector Research Unit (PAVRU), Department of Microbiology and Parasitology, University of Buea
(2)
Research Foundation for Tropical Diseases and the Environment (REFOTDE)
(3)
Scientific Networks and Ethics Promotion, Division of Health Operations Research, Ministry of Public Health
(4)
Institute of Medical Microbiology, Immunology and Parasitology (IMMIP), University Hospital of Bonn
(5)
German Centre for Infection Research (DZIF)

References

  1. Simonsen PE, Onapa AW, Asio SM. Mansonella perstans filariasis in Africa. Acta Trop. 2011;120:109–20.View ArticleGoogle Scholar
  2. Agbolade OM, Akinboye DO, Olateju TM, Ayanbiyi OA, Kuloyo OO, Fenuga OO. Biting of anthropophilic Culicoides fulvithorax (Diptera: Ceratopogonidae), a vector of Mansonella perstans in Nigeria. Korean J Parasitol. 2006;44:67–72.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Wanji S, Tendongfor N, Esum M, Ndindeng S, Enyong P. Epidemiology of concomitant infections due to Loa loa, Mansonella perstans and Onchocerca volvulus in rainforest villages of Cameroon. Med Microbiol Immunol. 2003;192:15–21.PubMedGoogle Scholar
  4. Bregani ER, Rovellini A, Mbaidoum N, Magnini MG. Comparison of different anthelminthic drug regimens against Mansonella perstans filariasis. Trans R Soc Trop Med Hyg. 2006;100:458–63.View ArticlePubMedGoogle Scholar
  5. Anosike JC, Dozie IN, Onwuliri CO, Nwoke BE, Onwuliri VA. Prevalence of Mansonella perstans infections among the nomadic Fulanis of northern Nigeria. Ann Agric Environ Med. 2005;12:35–8.PubMedGoogle Scholar
  6. Useh MF, Ejezie GC. The status and consequences of Mansonella perstans infection in Calabar. Nigeria East Afr Med J. 1995;2:124–6.Google Scholar
  7. Adalid-Peralta L, Fragoso G, Fleury A, Sciutto E. Mechanisms underlying the induction of regulatory T cells and its relevance in the adaptive immune response in parasitic infections. Int J Biol Sci. 2011;7:1412–26.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol. 2013;4:129.PubMedPubMed CentralGoogle Scholar
  9. Groux H, Cottrez F. The complex role of interleukin-10 in autoimmunity. J Autoimmun. 2003;20:281–5.View ArticlePubMedGoogle Scholar
  10. Asio SM, Simonsen PE, Onapa AW. Analysis of the 24-h microfilarial periodicity of Mansonella perstans. Parasitol Res. 2009;104:945–8.View ArticlePubMedGoogle Scholar
  11. Van Hoegaerden M, Ivanoff B, Flocard F, Salle A, Chabaud B. The use of mebendazole in the treatment of filariases due to Loa loa and Mansonella perstans. Ann Trop Med Parasitol. 1987;81(3):275–82.PubMedGoogle Scholar
  12. Simonsen PE, Fischer PU, Hoerauf A, Weil GJ. The Filariases. Manson's Tropical Diseases, 23rd edition. Philadelphia: Elsevier Saunders; 2013.Google Scholar
  13. Mommers EC, Dekker HS, Richard P, Garcia A, Chippaux JP. Prevalence of L. loa and M. perstans filariasis in southern Cameroon. Trop Geogr Med. 1995;47:2–5.PubMedGoogle Scholar
  14. Rhett B. Types of rainforests. 2012. Rainforests.mongabay.com/0103.htm.Google Scholar
  15. Centers for Disease Control and Prevention. Mansonellosis treatment and diagnosis information. 2013. http://www.cdc.gov/dpdx/mansonellosis/tx.html.Google Scholar
  16. Sasa M. Microfilaria survey methods and analysis of survey data in filariasis control programmes. Bull WHO. 1967;37:629–65.PubMedPubMed CentralGoogle Scholar
  17. Ohirel TA, Ranachandran CP. Planches pour l’identification des filaires. Geneva: World Health Organization; 1997. p. 1–6.Google Scholar
  18. Akue JP, Nkoghe D, Padilla C, Moussavou G, Moukana H, Mbou RA, Ollomo B, Leroy EM. Epidemiology of concomitant infection Due to Loa loa and Mansonella perstans in Gabon. PLoS Negl Trop Dis. 2011;5, e1329.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Noireau F, Carme B, Apembet JD, Gouteux JP. Loa loa and Mansonella persfans filariasis in the Chaillu Mountains, Congo: parasitological prevalence. Trans R Soc Trop Med Hyg. 1989;83:529–34.View ArticlePubMedGoogle Scholar
  20. Tatuene KJ, Fotsing RG, Nkoa T, Mbougua JB, Djeunga HC, Bopda J, Kamgno J. Epidemiology of Loa loa and Mansonella perstans filariasis in the Akonolinga Health District, Centre Region. Cameroon Health Sci Dis. 2014;15:1–5.Google Scholar
  21. Asio SM, Simonsen PE, Onapa AW. Mansonella perstans filariasis in Uganda: patterns of microfilaraemia and clinical manifestations in two endemic communities. Trans R Soc Trop Med Hyg. 2009;103:266–73.View ArticlePubMedGoogle Scholar
  22. Kyelem D, Sanou S, Boatin B, Medlock J, Coulibaly S, Molyneux DH. Impact of long-term ivermectin (Mectizan) on Wuchereria bancrofti and Mansonella perstans infections in Burkina Faso: strategic and policy implications. Ann Trop Med Parasitol. 2003;97:827–38.View ArticlePubMedGoogle Scholar
  23. Kyelem D, Medlock J, Sanou S, Bonkoungou M, Boatin B, Molyneux DH. Short communication: impact of long-term (14 years) bi-annual ivermectin treatment on Wuchereria bancrofti microfilaraemia. Trop Med Int Health. 2005;10:1002–4.View ArticlePubMedGoogle Scholar
  24. Fischer P, Kilian AH, Bamuhiiga J, Kipp W, Büttner DW. Prevalence of Mansonella perstans in western Uganda and its detection using the QBC-fluorescence method. Appl Parasitol. 1996;37:32–7.PubMedGoogle Scholar
  25. Schulz-Key H, Albrecht W, Heuschkel C, Soboslay PT, Banla M, Görgen H. Efficacy of ivermectin in the treatment of concomitant Mansonella perstans infections in onchocerciasis patients. Trans R Soc Trop Med Hyg. 1993;227–229.Google Scholar
  26. Metenou S, Babu S, Nutman TB. Impact of filarial infections on coincident intracellular pathogens: Mycobacterium tuberculosis and Plasmodium falciparum. Curr Opin HIV AIDS. 2012;7(3):231–8.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Aw O, Simonsen PE, Baehr I, Pedersen EM. Rapid assessment of the geographical distribution of Mansonella perstans infections in Uganda by screening school children for microfilariae. Ann Trop Med Parasitol. 2005;99(4):383–93.View ArticleGoogle Scholar
  28. Wanji S, Kengne-Ouafo JS, Esum ME, Chounna PN, Adzemye BF, Eyong JE, Jato I, Datchoua-Poutcheu FR, Abong AR, Enyong P, Taylor DW. Relationship between oral declaration on adherence to ivermectin treatment and parasitological indicators of onchocerciasis in an area of persistent transmission despite a decade of mass drug administration in Cameroon. Parasite Vectors. 2015;8:667.View ArticleGoogle Scholar
  29. Kengne-Ouafo JA, Nji TM, Tantoh WF, Nyoh DN, Tendongfor N, Enyong PA, Newport MJ, Davey G, Wanji S. Perceptions of consent, permission structures and approaches to the community: a rapid ethical assessment performed in North West Cameroon. BMC Public Health. 2014;14:1026.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Advertisement